Lenacapavir is a long-acting antiretroviral drug that works differently from existing HIV medications
The introduction of a revolutionary drug, Lenacapavir, is poised to alter the landscape of healthcare across sub-Saharan Africa, where the HIV burden remains highest.
Kenya, with an estimated 1.4 million people living with HIV, stands to benefit significantly from the drug’s unique formulation and long-acting delivery.
Help us continue bringing you unbiased news, in-depth investigations, and diverse perspectives. Your subscription keeps our mission alive and empowers us to provide high-quality, trustworthy journalism. Join us today to make a difference!
